Close on Sep 18, 2026. Page updated Sep 19, 9:15 pm ET.
Pfizer closes at $27.66, up 0.1%, sitting above both its 50-day average of $26.62 and 200-day average of $26.27, consistent with a supportive trend. The GekkoIndex reads 57.1, placing the stock in the Neutral zone with a five-day change of -0.9. Price stands 9.8% below Gekko Fair Value of $30.68.
This week's news centers on portfolio moves and regulatory clearances rather than a single dominant catalyst. Novartis India has agreed to buy Pfizer's Minipress (prazosin) brands for $150 million, giving Novartis full ownership of the hypertension franchise in that market. Separately, Health Canada has authorized the Pfizer-BioNTech Omicron XFG-adapted COMIRNATY vaccine for individuals aged 6 months and older ahead of the 2026-2027 season. Additional coverage has focused on the dividend, questioning whether the payout, which has risen annually for over a decade, can continue growing, alongside commentary on the stock's broader ~6% yield and near-term direction.
Pfizer's next earnings report is scheduled for 3 November 2026, 44 days out and beyond a typical 20-trading-day hold. Over the last 90 days, insiders made 3 open-market purchases totaling $2,960,110, and Congress recorded 1 buy and 0 sells. Seasonality is a headwind: over 5 years, the next 20 trading days from this point averaged -2.5%, rising in only 1 of those years. Analyst consensus among 21 firms includes 8 buy, 12 hold and 1 sell ratings, with a consensus target of $28.88.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Pfizer scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
Above 50 and 200-day
Close $27.66 is above the 50-day ($26.62) and 200-day ($26.27) averages, and the 50-day is above the 200-day.
See the chart57.1, Neutral
Reading 57.1 is in the Neutral zone.
See the GekkoIndex9.8% below
Price is 9.8% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 90 days: 3 open-market insider purchases; Congress 1 buy / 0 sales.
See smart moneyReports in 44 days
Next report Nov 3, 2026, 44 days away — outside a typical 20-trading-day hold.
See earnings−2.5% on average
From this point in the calendar, the next 20 trading days averaged −2.5% over 5 years, rising in 1 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Pfizer closed at $27.66 on Sep 18, 2026, +15.0% over the past year, inside a 52-week range of $23.58 to $29.21.
Use the left and right arrow keys to read daily values.
Put PFE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Pfizer develops, manufactures and sells medicines and vaccines across a broad range of health conditions. Its work spans heart and women's health treatments, biologic and small-molecule drugs, immunotherapies, and biosimilars, with brands such as Eliquis, Ibrance, Xtandi and Retacrit among its recognized names. The company is also known for Paxlovid, its oral COVID-19 treatment, and for vaccines including Comirnaty and the Prevnar line, which cover diseases such as pneumococcal and meningococcal infection and tick-borne encephalitis.
Beyond its own branded products, Pfizer runs a contract manufacturing arm and produces biosimilars for autoimmune and inflammatory disorders, alongside treatments for rare conditions like amyloidosis and hemophilia. Its customers include wholesalers, hospitals, clinics, pharmacies, government bodies and individual medical practices, and it works with partners such as Bristol-Myers Squibb, BioNTech and Merck KGaA on various programs.
Founded in 1849 and headquartered in New York, New York, Pfizer's shares are listed on the NYSE under the ticker PFE.
Pfizer’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57.1, in the Neutral zone, down 0.9 points over five sessions.
Down 0.9 points over five sessions.
Reading for Sep 18, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 41 | −0.4% | +1.4% | ||
| Accumulation | 224 | +0.7% | +1.2% | ||
| Neutral (current zone) | 381 | −0.2% | −0.4% | ||
| Distribution | 15 | −2.8% | −5.6% | ||
| Selling | 1 | Too few readings yet | |||
Average PFE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Pfizer trades 9.8% below Gekko Fair Value of $30.68, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Pfizer shares are worth, recalculated every trading day.
$30.68
Gekko Fair Value, Sep 19, 2026
9.8% Undervalued
Insiders filed 3 open-market purchases in Pfizer worth $2.96M, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
$2.96Min 3 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 12 | Albert Bourla Chairman & CEO | Purchase | $1.00M |
| Aug 5 | Ronald E Blaylock Director | Purchase | $999K |
| Aug 5 | Mortimer J Buckley Director | Purchase | $960K |
From Form 4 filings, dated to when each was filed.
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Aug 12 traded Jul 7 |
From congressional disclosures, which report amounts as ranges.
Pfizer has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds PFE.
Pfizer reports on Nov 3, 2026 (44 days away), and beat the EPS estimate in 8 of its last 8 reports.
Nov 3, 2026
44 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | $0.77 est $0.68 | $15.03B est $14.40B | +3.1% |
| May 5, 2026 | $0.75 est $0.72 | $14.45B est $13.84B | +0.9% |
| Feb 3, 2026 | $0.66 est $0.57 | $17.56B est $16.85B | +0.5% |
| Nov 4, 2025 | $0.87 est $0.63 | $16.65B est $16.50B | −0.2% |
| Aug 5, 2025 | $0.78 est $0.58 | $14.65B est $13.56B | +1.7% |
| Apr 29, 2025 | $0.92 est $0.67 | $13.72B est $13.92B | +5.9% |
| Feb 4, 2025 | $0.63 est $0.47 | $17.76B est $17.35B | +0.9% |
| Oct 29, 2024 | $1.06 est $0.61 | $17.70B est $14.92B | −1.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Pfizer is $28.88, +4.4% from the last close, from 21 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 21 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 10 | HSBC | $30 | +8.5% |
| Aug 24 | Scotiabank | $30 | +8.5% |
| Aug 20 | Bernstein | $29 | +4.8% |
| Aug 17 | BMO Capital | $30 | +8.5% |
| Aug 13 | Barclays | $25 | −9.6% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Sep 19, Pfizer averaged −2.5% across the last 5 years, rising in 1 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.7% | 0 of 5 |
| Next 10 trading days | +0.6% | 1 of 5 |
| Next 15 trading days | −2.1% | 2 of 5 |
| Next 20 trading days | −2.5% | 1 of 5 |
| Next 30 trading days | −2.1% | 2 of 5 |
For scale, PFE’s typical 20-trading-day move in either direction is about 4.6%.
Pfizer’s market cap is $157.3B, with a P/E ratio of 35.9 and revenue of $63.70B over the last twelve months.
Coverage of Pfizer this week reads positive: 5 positive, 3 neutral and 2 negative headlines.
Pfizer’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Accumulation | 15.7% above |
| JNJJohnson & Johnson | Neutral | 2.7% below |
| ABBVAbbVie | Neutral | 22.6% above |
| MRKMerck | Neutral | 7.3% below |
| AZNAstraZeneca | Neutral | 41.0% below |
| VRTXVertex Pharmaceuticals | Accumulation | 9.7% above |
A peer links to its own page where one exists.
Pfizer’s market cap is $157.3B at the Sep 18, 2026 close of $27.66, with 5.70B shares outstanding. The shares trade on a P/E ratio of 35.9.
The consensus analyst 12-month price target for Pfizer is $28.88, +4.4% from the last close. Of the 21 firms that rated the stock in the last 90 days, 8 rate it a buy, 12 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Pfizer is undervalued: the Sep 18, 2026 close of $27.66 is 9.8% below Gekko Fair Value of $30.68. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Pfizer is expected to report on Nov 3, 2026 (44 days away). Analysts expect earnings of $0.79 per share on revenue of $15.93B. Pfizer beat the earnings estimate in 8 of its last 8 reports, moving 1.8% on average across the report.
Pfizer’s 52-week high is $29.21 and its 52-week low is $23.58; it closed at $27.66 on Sep 18, 2026, +15.0% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, fair value, smart money and earnings risk), 1 as mixed (gekkoindex) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.